AngioDynamics Stock Price, News & Analysis (NASDAQ:ANGO)

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) announced its quarterly earnings results on Thursday, October, 3rd. The medical instruments supplier reported $0.08 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.04 by $0.04. The medical instruments supplier earned $66 million during the quarter, compared to the consensus estimate of $67.74 million. AngioDynamics had a return on equity of 4.89% and a net margin of 17.79%. The firm's quarterly revenue was up 3.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.16 earnings per share. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Friday, January 3rd 2020. View Earnings Estimates for AngioDynamics.

AngioDynamics updated its FY20 earnings guidance on Thursday, October, 3rd. The company provided earnings per share guidance of $0.10-0.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.26. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $281.89 million.

2 analysts have issued 1 year price targets for AngioDynamics' shares. Their forecasts range from $21.00 to $23.00. On average, they anticipate AngioDynamics' share price to reach $22.00 in the next twelve months. This suggests a possible upside of 52.1% from the stock's current price. View Analyst Price Targets for AngioDynamics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AngioDynamics.

Media headlines about ANGO stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AngioDynamics earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave headlines about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for AngioDynamics.

AngioDynamics saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 1,130,000 shares, a decline of 17.5% from the August 30th total of 1,370,000 shares. Based on an average daily volume of 235,900 shares, the days-to-cover ratio is presently 4.8 days. Currently, 3.1% of the company's shares are sold short. View AngioDynamics' Current Options Chain.

Some companies that are related to AngioDynamics include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Hologic (HOLX), Steris (STE) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include Oasis Petroleum (OAS), General Electric (GE), Intel (INTC), Mattel (MAT), Chesapeake Energy (CHK), Centurylink (CTL), DIGITAL RLTY TR/SH (DLR), Hanesbrands (HBI), Kimco Realty (KIM) and Regions Financial (RF).

AngioDynamics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Tributary Capital Management LLC (1.80%), Fenimore Asset Management Inc. (1.52%), Envestnet Asset Management Inc. (0.17%), Virginia Retirement Systems ET AL (0.16%), Assenagon Asset Management S.A. (0.15%) and Strs Ohio (0.09%). Company insiders that own AngioDynamics stock include Kevin J Gould and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Brinker Capital Inc. and Strs Ohio. Company insiders that have sold AngioDynamics company stock in the last year include Kevin J Gould and Michael Greiner. View Insider Buying and Selling for AngioDynamics.

ANGO stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Meeder Asset Management Inc., State of Alaska Department of Revenue, Pacer Advisors Inc., Nisa Investment Advisors LLC, Campbell & CO Investment Adviser LLC, Envestnet Asset Management Inc. and Virginia Retirement Systems ET AL. View Insider Buying and Selling for AngioDynamics.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANGO stock can currently be purchased for approximately $14.46.

AngioDynamics has a market capitalization of $543.99 million and generates $359.48 million in revenue each year. The medical instruments supplier earns $61.34 million in net income (profit) each year or $0.83 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.View Additional Information About AngioDynamics.

The official website for AngioDynamics is http://www.angiodynamics.com/.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]